Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · Real-Time Price · USD

2.410

+0.010 (0.42%)

Aug 6, 2026, 4:00 PM EDT - Market closed

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	49.57	139.22	56.49	9.17	7.19	40.75
Short-Term Investments	120.8	39.54	41.05	4.09	15.86	-
Cash & Short-Term Investments	170.37	178.76	97.54	13.25	23.05	40.75
Cash Growth	82.84%	83.27%	636.06%	-42.51%	-43.44%	192.04%
Accounts Receivable	-	-	-	-	0.04	0.11
Other Current Assets	1.81	1.35	0.91	0.96	1.28	1.61
Total Current Assets	172.18	180.11	98.45	14.21	24.37	42.47
Net Property, Plant & Equipment	-	-	0.15	0.3	0.57	-
Other Long-Term Assets	1.16	1.1	-	-	-	-
Total Assets	173.33	181.2	98.6	14.51	24.94	42.47

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	1.59	1.16	0.94	0.65	1.15	1.09
Accrued Expenses	4.12	4.08	2.68	2.26	2.4	2.72
Short-Term Debt	-	-	-	0.38	-	0.25
Current Portion of Leases	-	-	0.11	0.15	0.15	-
Other Current Liabilities	-	3.06	-	-	-	-
Total Current Liabilities	5.71	8.3	3.73	3.44	3.7	4.05
Long-Term Leases	-	-	-	0.09	0.21	-
Total Long-Term Liabilities	-	-	-	0.09	0.21	-
Total Liabilities	5.71	8.3	3.73	3.53	3.9	4.05

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.13	0.13	0.07	0.01	0	0.03
Additional Paid-in Capital	326.58	315.43	189.25	77.87	68.8	68.21
Accumulated Other Comprehensive Income	-0.03	0.02	-0.04	0	0.1	-
Retained Earnings	-159.06	-142.68	-94.42	-66.9	-47.87	-29.82
Shareholders' Equity	167.62	172.9	94.87	10.98	21.04	38.42
Total Liabilities & Equity	173.33	181.2	98.6	14.51	24.94	42.47

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	-	0	0.11	0.62	0.35	0.25
Net Cash (Debt)	170.37	178.76	97.43	12.63	22.7	40.5
Net Cash Growth	82.98%	83.47%	671.44%	-44.36%	-43.95%	197.05%
Net Cash Per Share	1.43	1.82	4.11	2.10	5.38	13.35
Book Value	167.62	172.9	94.87	10.98	21.04	38.42
Book Value Per Share	1.41	1.76	4.00	1.82	4.98	12.66
Tangible Book Value	167.62	172.9	94.87	10.98	21.04	38.42
Tangible Book Value Per Share	1.41	1.76	4.00	1.82	4.98	12.66

SEC Filings: 10-K · 10-Q